Related by context. All words. (Click for frequent words.) 68 neoadjuvant chemotherapy 68 neoadjuvant treatment 67 liver resection 66 TACE 66 metastatic RCC 65 chemoradiotherapy 65 concurrent chemoradiation 65 radiotherapy RT 64 neoadjuvant 64 radical nephrectomy 64 ribavirin RBV 64 chemoradiation therapy 64 chemoradiation 64 CRp 64 autologous stem cell 64 metastatic CRC 64 estramustine 63 metastatic renal cell carcinoma 63 cytoreduction 63 VELCADE melphalan 63 intravesical therapy 63 heavily pretreated patients 63 PEG IFN 63 remission induction 63 chlorambucil 63 radical cystectomy 63 transplant ASCT 63 recurrent GBM 63 total thyroidectomy 63 biochemical relapse 63 recurrent NSCLC 63 colorectal liver metastases 63 tumor resection 63 coronary intervention 62 stage IIIB 62 cytoreductive nephrectomy 62 lymphadenectomy 62 neoadjuvant therapy 62 doxorubicin docetaxel 62 CR CRu 62 hepatic metastases 62 NMIBC 62 relapsed MM 62 CHOP chemotherapy 62 postoperative chemotherapy 62 metastatic malignant 62 dose dexamethasone 62 adjuvant tamoxifen 62 ABVD 62 melphalan prednisone 62 laparoscopic radical nephrectomy 62 Doxil ® 62 debulking surgery 62 TURBT 62 intravesical 62 abiraterone acetate 62 dose melphalan 62 carboplatin paclitaxel 62 somatostatin analog 62 adjuvant radiotherapy 61 cytotoxic therapy 61 multiple myeloma MM 61 fludarabine cyclophosphamide 61 CIMZIA TM 61 relapsed refractory 61 CsA 61 tenecteplase 61 5FU 61 subconjunctival injection 61 plus dexamethasone 61 VNP#M 61 external beam radiotherapy 61 fibrinolysis 61 APTIVUS r 61 EBRT 61 chemotherapy docetaxel 61 mg kg dose 61 adjuvant radiation 61 tamoxifen therapy 61 androgen blockade 61 imatinib therapy 61 plus prednisone 60 cystectomy 60 vidofludimus 60 oblimersen 60 anthracycline taxane 60 MabCampath 60 Xanafide 60 thalidomide Thalomid 60 HER2 positive metastatic breast 60 lenalidomide dexamethasone 60 PSA nadir 60 placebo dexamethasone 60 colorectal cancer liver metastases 60 refractory CLL 60 transarterial chemoembolization 60 liposomal doxorubicin 60 recurrent glioblastoma multiforme 60 dose cytarabine 60 biliary tract cancer 60 unresectable 60 huN# DM1 60 preoperative chemotherapy 60 assessing T DM1 60 viral kinetics 60 dacarbazine 60 CLL SLL 60 PegIFN RBV 60 bendamustine 60 allogeneic stem cell 60 stage IIIb IV 60 Fludara 60 antithymocyte globulin 60 Gemcitabine 60 OPCAB 60 Amrubicin 60 PegIFN 60 Irinotecan 60 mRCC 60 gemcitabine Gemzar ® 60 liver metastases 60 histologically confirmed 60 clinically localized prostate 60 RRMS patients 60 nephrectomy 60 gefitinib 60 DMARD 60 refractory AML 60 VGPR 60 phase IIb clinical 60 leukemia AML 60 comparator arm 60 platinum refractory 60 myocardial revascularization 60 desvenlafaxine succinate 59 Neoadjuvant 59 azacitidine 59 advanced hepatocellular carcinoma 59 underwent resection 59 surgical debulking 59 Telintra 59 tirofiban 59 mitomycin C 59 Acute Coronary Syndromes ACS 59 remission CR 59 temsirolimus 59 autologous SCT 59 locoregional disease 59 pegylated liposomal doxorubicin 59 paclitaxel carboplatin 59 IV NSCLC 59 heavily pretreated 59 eptifibatide 59 lymph node dissection 59 allogeneic SCT 59 FOLPI 59 fibrinolytic therapy 59 #mg/m# [001] 59 partial remissions 59 preoperative radiotherapy 59 FOLFOX4 59 Traficet EN 59 fluorouracil 59 cisplatin chemotherapy 59 HSCT 59 severe oral mucositis 59 mCRC patients 59 androgen suppression 59 Flu Cy 59 Elitek 59 hepatectomy 59 5-fluorouracil/leucovorin 59 biochemical recurrence 59 bevacizumab Avastin ® 59 Thrombolysis 59 Pegylated Liposomal Doxorubicin 59 BCG refractory 59 cytotoxic chemotherapy 59 relapsed refractory multiple myeloma 59 curative resection 59 antithrombotic therapy 59 lenalidomide Revlimid R 59 receptor tyrosine kinase inhibitor 59 placebo controlled clinical 59 Pemetrexed 59 primary patency 59 CR nPR 59 MGd 59 Ceplene/IL-2 59 Phase Ib study 59 renal tumors 59 phase IIb trial 59 decitabine 59 carotid endarterectomy CEA 59 sunitinib malate 59 Lenalidomide 59 cisplatin vinorelbine 59 allogeneic hematopoietic stem cell 59 complete remissions 59 HRPC 59 CIMZIA ™ 59 Renal Cell Carcinoma RCC 59 immunomodulatory therapy 59 unfractionated heparin UFH 59 sorafenib Nexavar 59 DMARD therapy 59 bosutinib 59 nadolol 59 pegylated interferon alfa 59 pT2 59 #mg QD [002] 59 cytogenetic response 59 HGS# 59 docetaxel Taxotere ® 59 vinorelbine 59 AGGRASTAT ® 59 resectable 58 mapatumumab 58 doxorubicin cyclophosphamide 58 goserelin 58 DAPT 58 8mg/kg 58 papillary renal cell carcinoma 58 APTIVUS R 58 nonmetastatic prostate cancer 58 resminostat 58 oral allopurinol 58 randomized #:#:# 58 gemcitabine carboplatin 58 REVIVE Diabetes 58 dalteparin 58 dexamethasone Decadron 58 postintervention 58 intra arterial 58 omacetaxine mepesuccinate 58 Fludarabine 58 metastatic renal cell 58 MitraClip device 58 pamidronate 58 lumiliximab 58 sirolimus eluting stents 58 nab paclitaxel 58 cell lymphoma CTCL 58 docetaxel Taxotere 58 relapsing multiple sclerosis 58 Castration Resistant Prostate Cancer 58 mg/m2 cohort 58 trabectedin 58 Cyclophosphamide 58 transurethral resection 58 tinzaparin 58 Phase Ib clinical 58 pCR 58 morphometric vertebral fractures 58 iodixanol 58 pT3 58 elective PCI 58 ZACTIMA 58 5-FU/LV 58 DEB# 58 untreated multiple myeloma 58 biologic DMARD 58 SCCHN 58 SIR Spheres 58 Fludara ® 58 evaluable subjects 58 myelodysplastic syndrome MDS 58 Platinol ® cisplatin 58 transplantation ASCT 58 CA4P 58 cinacalcet 58 axitinib 58 glatiramer acetate 58 etoposide 58 TURP 58 lung metastases 58 daunorubicin 58 sunitinib 58 Dyloject TM 58 rFSH 58 idarubicin 58 FOLFOX6 58 KRAS mutations occur 58 Free Survival PFS 58 Retreatment 58 myeloablative 58 tumors GIST 58 gemcitabine Gemzar 58 hematologic toxicity 58 metastatic colorectal carcinoma 58 ara C 58 adjuvant therapy 58 PSMA ADC 58 XIENCE V stent 58 adjuvant cisplatin 58 Resection 58 lobectomy 58 radical prostatectomy RP 58 interferon ribavirin 58 daily subcutaneous injections 58 total abdominal hysterectomy 58 recanalization 58 tumor regressions 58 evaluating tivozanib 58 adenoma recurrence 58 docetaxel Taxotere R 58 Torisel 58 HepaSphere 58 Mantle Cell Lymphoma 58 relapsed multiple myeloma 58 BrachySil TM 58 bortezomib refractory 58 YONDELIS 58 capecitabine Xeloda 58 TEMODAL 58 mitoxantrone plus 58 dacarbazine DTIC 58 progression TTP 58 gemcitabine cisplatin 58 SLNB 58 XELOX 58 colectomy 58 colorectal carcinoma 58 diagnosed multiple myeloma 58 DOXIL 58 Phase #b/#a trial 58 peg interferon 58 CYT# potent vascular disrupting 58 Gliadel Wafer 58 metastatic pancreatic 58 advanced unresectable 58 transfemoral 58 pegylated interferon alfa 2b 57 locoregional 57 evaluable patients 57 sunitinib Sutent 57 intravesical chemotherapy 57 ixabepilone 57 pulmonary artery banding 57 mycophenolate mofetil 57 achieved ACR# 57 cortical stimulation 57 thrombolytics 57 ritonavir boosted 57 erlotinib Tarceva ® 57 dasatinib Sprycel 57 peginterferon alfa 2a #KD 57 telaprevir dosed 57 metastatic GIST 57 rFVIIa 57 crizotinib PF # 57 thalidomide dexamethasone 57 CRu 57 primary percutaneous coronary 57 β blockers 57 nonresponders 57 trastuzumab 57 polycythemia vera essential thrombocythemia 57 CALGB # [002] 57 adalimumab Humira 57 phase IIb study 57 HBeAg + 57 cytoreductive surgery 57 nephron sparing surgery 57 receiving highly emetogenic 57 temozolomide TMZ 57 transarterial 57 paclitaxel eluting stents 57 virologic failure 57 acute GvHD 57 saphenous vein graft 57 Mitoxantrone 57 XIENCE V PROMUS Stent 57 olmesartan 57 DCVax ® Brain 57 L PPDS 57 micafungin 57 Hycamtin ® 57 apremilast 57 nodular partial response 57 pegylated liposomal doxorubicin PLD 57 beta 1a 57 tumor lysis syndrome 57 eplerenone 57 #Gy 57 docetaxel prednisone 57 adrenalectomy 57 alteplase 57 Cloretazine 57 multikinase inhibitor 57 temozolomide 57 SLN biopsy 57 locoregional recurrence 57 OvaRex MAb 57 IGF 1R inhibitor 57 epirubicin cyclophosphamide 57 dose escalation phase 57 CHAMPION PCI 57 docetaxel 57 dosing cohorts 57 CINTREDEKIN BESUDOTOX 57 plus gemcitabine 57 Urocidin ™ 57 sirolimus eluting stent 57 drotrecogin alfa activated 57 Trastuzumab 57 autologous chondrocyte implantation 57 MVax 57 glycoprotein IIb IIIa inhibitors 57 oral antiplatelet therapy 57 achieved CCyR 57 Carotid 57 hepatic resection 57 Phase III randomized controlled 57 antithrombotic 57 OZURDEX ® 57 postoperative radiotherapy 57 endoscopic resection 57 metastatic malignant melanoma 57 Pegasys plus Copegus 57 herpetic keratitis 57 Complete Response CR 57 mitoxantrone 57 microbiological eradication 57 chemotherapeutic regimen 57 Tamibarotene 57 zalutumumab 57 CTEPH 57 coronary stenting 57 mCi kg 57 FOLFOX chemotherapy 57 Hepatocellular Carcinoma HCC 57 Revlimid lenalidomide 57 IFN alfa 57 EOquin TM 57 fosbretabulin 57 oral rivaroxaban 57 randomized Phase IIb 57 Raptiva r 57 recurrent metastatic 57 CCyR 57 Capecitabine 57 octreotide 57 azilsartan medoxomil 57 dose cohort 57 nonmetastatic 57 EOquin 57 ACTEMRA TM 57 hepatocellular cancer 57 evaluable 57 interferon alfa 2a 57 lanreotide 57 chemoembolization 57 velafermin 57 zonisamide SR 57 Natalizumab 57 renal transplantation 57 beta blocker therapy 57 methotrexate therapy 57 Erlotinib 57 Fontan procedure 57 paclitaxel eluting stent 57 Q#IR 57 docetaxel chemotherapy 57 dosing cohort 57 Induction Chemotherapy 57 ritonavir boosted lopinavir 57 prostate cancer CaP 57 undetectable HBV DNA 57 superficial bladder cancer 57 Acute Ischemic Stroke 57 FIRMAGON 57 plus MTX 56 Phase 1a clinical 56 mitomycin 56 trabeculectomy 56 Melphalan 56 intracoronary 56 androgen deprivation 56 ALND 56 Aptivus ® 56 colorectal adenoma 56 imatinib 56 demonstrated antitumor activity 56 myocardial necrosis 56 relapsed CLL 56 coronary revascularization 56 patients evaluable 56 LEXIVA r 56 completely resected 56 lymphocytosis 56 bortezomib 56 ORAL HYCAMTIN 56 definite stent thrombosis 56 standard chemotherapy regimen 56 FluCAM 56 extrapleural pneumonectomy 56 taxane therapy 56 ERCP 56 mg QD 56 patients undergoing CABG 56 hepatocellular carcinoma HCC 56 lesional 56 PD LID 56 low dose cytarabine 56 paclitaxel Taxol R 56 R0 resection 56 pelvic lymphadenectomy 56 paricalcitol 56 LMWH 56 randomized blinded 56 BRIM2 56 peginterferon 56 recurrent prostate cancer 56 Phase IIIb clinical 56 prior chemotherapy regimens 56 adriamycin 56 drug eluting stent DES 56 Halaven 56 Velcade bortezomib 56 Advagraf 56 anthracycline containing 56 taxane chemotherapy 56 methotrexate monotherapy 56 noninferior 56 refractory colorectal cancer 56 MEND CABG II 56 rt PA 56 ZYBRESTAT TM 56 metastatic bladder 56 GP IIb IIIa inhibitors 56 glycoprotein IIb IIIa inhibitor 56 IFN α 56 recurrent malignant glioma 56 dasatinib Sprycel ® 56 FOLFIRI 56 meniscectomy 56 periprocedural 56 Pharmacokinetics PK 56 tumor necrosis 56 virological response 56 aPTT 56 everolimus eluting stents 56 TNF inhibitor 56 ARB telmisartan 56 NSTE ACS 56 palifermin 56 autologous hematopoietic stem cell 56 ibandronate 56 pelvic lymph node dissection 56 Sanvar R 56 localized renal 56 autologous transplant 56 flutamide 56 segmentectomy 56 prostate carcinoma 56 randomized #:# 56 reteplase 56 prospectively defined 56 TAXUS Liberté stent 56 efficacy endpoint 56 calcineurin inhibitor 56 TORISEL 56 fallopian tube cancers 56 intradermal injections 56 extracranial 56 ACR# responses 56 CCX# B 56 radiochemotherapy 56 imatinib mesylate 56 Kaplan Meier analysis 56 Mitomycin C 56 Triapine R 56 Arzerra ofatumumab 56 carotid artery stenting CAS 56 pharmacodynamic PD 56 peg IFN 56 pertuzumab 56 irbesartan 56 comparator PI r 56 HoLEP 56 sipuleucel T 56 non squamous NSCLC 56 PANVAC VF 56 pegylated interferon peg IFN 56 recurrent glioblastoma 56 anterior lumbar interbody fusion 56 metastatic hormone refractory 56 paroxysmal AF 56 transurethral 56 extranodal 56 node dissection 56 TKI therapy 56 Degarelix 56 COPAXONE ® 56 refractory metastatic 56 follicular NHL 56 systemic ALCL 56 eluting stent 56 nodal dissection 56 transplantation HCT 56 NATRECOR R 56 transthoracic 56 metastatic castration resistant 56 mcg QD 56 neurologic progression 56 generation purine nucleoside 56 Topotecan 56 Metastatic Renal Cell Carcinoma 56 transitional cell carcinoma 56 complete cytogenetic response 56 intravenous dosing 56 surgical revascularization 56 pneumonectomy 56 alfa 2a 56 Tarceva TM 56 allogeneic bone marrow 56 thromboembolic events 56 angioplasty stenting 56 LB# [003] 56 EBMT criteria 56 Surgical resection 56 tamsulosin 56 metastatic HRPC 56 trans urethral resection 56 Tacrolimus 56 mutated KRAS 56 prospectively evaluated 56 ThermoDox R 56 AGILECT R 56 underwent surgical resection 56 pediatric Crohn disease 56 BR.# 56 relapsed ovarian cancer 56 relapsed MCL 56 fibrinolytic 56 Myelodysplastic Syndrome MDS 56 Cladribine tablets 56 radiation sensitizer 56 Gefitinib 56 stent implantation 56 infusional 5-FU/LV 56 ABSORB trial 56 thymoma 56 mTOR inhibitor 56 peritoneal carcinomatosis 56 caspofungin 56 EFAPROXYN 56 Hsp# Inhibitor 56 pain palliation 56 GRASPA ® 56 Prochieve R 8 56 paclitaxel Taxol ® 56 teriflunomide 56 HBeAg positive patients 56 intra arterial chemotherapy 56 pioglitazone HCl 56 epirubicin 56 elacytarabine 56 plus methotrexate 56 gemcitabine 56 CABG 55 ISTODAX 55 RECIST Response Evaluation Criteria 55 differentiated thyroid 55 paclitaxel poliglumex 55 median sternotomy 55 Exemestane 55 lanthanum carbonate 55 Pegylated Interferon 55 AGILECT ® 55 HBeAg seroconversion 55 Oxaliplatin 55 xenograft models 55 trastuzumab Herceptin ® 55 basal cell carcinoma BCC 55 Endeavor DES 55 methotrexate MTX 55 rilonacept 55 virological failure 55 irinotecan chemotherapy 55 pancreatic adenocarcinoma 55 LV dysfunction 55 inhaled treprostinil 55 Dacogen injection 55 CVP chemotherapy 55 cyclophosphamide methotrexate 55 relapsed AML 55 Vascugel ® 55 maximal dose 55 VAPRISOL 55 Folfox 55 4mg/kg 55 Zemplar Capsules 55 EGFR TKIs 55 intralesional 55 diagnosed GBM 55 fondaparinux 55 cetuximab Erbitux R 55 Neupogen ® 55 Cloretazine ® 55 mTOR inhibitors 55 PAOD 55 neointimal hyperplasia 55 F FDG PET 55 Decitabine 55 Platinol ® 55 TroVax ® 55 hypofractionated 55 Bezielle 55 phase IIa clinical 55 fallopian tube carcinoma 55 pancreatectomy 55 AQ4N 55 Dose escalation 55 mg qd 55 cilostazol 55 fludarabine 55 pomalidomide 55 SNT MC# 55 pegylated interferon alpha 55 ureteroscopy 55 MYLOTARG 55 Peg IFN 55 agalsidase alfa 55 histamine dihydrochloride 55 Aflibercept 55 depsipeptide 55 indolent NHL 55 BEACOPP 55 posaconazole 55 transplantation HSCT 55 refractory metastatic colorectal cancer 55 refractory ovarian cancer 55 ribavirin therapy 55 FOLFOX regimen 55 volociximab 55 ePTFE graft 55 APTIVUS 55 Interferon alfa 55 double blinded placebo 55 randomized Phase 2b 55 dacarbazine chemotherapy 55 radioiodine therapy 55 CZP 55 unresectable HCC 55 Partial Response 55 liver metastasis 55 LEUKINE 55 abciximab 55 colorectal carcinomas 55 dose clopidogrel 55 epoetin alpha 55 cangrelor 55 EGFR TKI 55 IFN beta 55 disease progression TTP 55 anthracyclines taxanes 55 VATS lobectomy 55 IIa trial 55 tocilizumab 55 melphalan 55 carotid artery stenting 55 Vascugel 55 ALA PDT 55 intravenous bisphosphonates 55 sustained virological response 55 thyroidectomy 55 COPAXONE R 55 BLA filing 55 NFV 55 Zilver PTX stent 55 previously untreated follicular 55 bi ventricular pacing 55 pegaptanib 55 dasatinib 55 lung resection 55 gefitinib Iressa 55 weekly subcutaneous injections 55 NSTEMI 55 CLARITY study 55 SPRYCEL ® 55 Platinol 55 p = NS 55 adjuvant chemotherapy 55 xanthine oxidase inhibitor 55 talabostat 55 IIIA NSCLC 55 clodronate 55 Enzyme Replacement Therapy 55 refractory multiple myeloma 55 Accelerated Partial Breast Irradiation 55 R# #mg BID 55 familial amyloidotic polyneuropathy FAP 55 refractory NSCLC 55 ErbB2 positive 55 Cypher Stent 55 HIPEC 55 BENICAR HCT 55 Pegasys ® 55 Myocet 55 BRAF inhibitor 55 PEGylated interferon beta 1a 55 cisplatin gemcitabine 55 autologous transplantation 55 median PFS 55 esophagectomy 55 Zevalin R Ibritumomab 55 Augment Injectable 55 ON #.Na 55 squamous cell carcinoma SCC 55 HDACi 55 interferon IFN 55 novel oral anticoagulant 55 vandetanib 55 romidepsin 55 inhaled iloprost 55 dosage regimens 55 complete cytogenetic 55 perioperatively 55 GnRH antagonist 55 mycophenolate mofetil MMF 55 nicardipine 55 resection 55 IIb clinical trial 55 adalimumab 55 milatuzumab 55 PCNL 55 interferon beta therapy 55 HBeAg negative patients 55 CRRT 55 amrubicin 55 cytogenetic responses 55 Epirubicin 55 Urocidin 55 urate lowering therapy 55 CC genotype 55 Gleevec resistant 55 Taxotere ® 55 satraplatin Phase 55 ß blockers 55 atherothrombotic events 55 darunavir ritonavir 55 variceal hemorrhage 55 oral methylnaltrexone 55 elevated transaminases 55 Gleevec imatinib mesylate 55 antiplatelet agent 55 imatinib Gleevec ® 55 resected 55 IL#B 55 Phase IIa trials 55 fluoropyrimidine 55 Troxatyl 55 GLP toxicology studies 55 underwent radical cystectomy 55 monotherapy 55 refractory DLBCL 55 riociguat 55 NOD SCID mice 55 FDG-PET/CT 55 INC# 55 bypass grafting 55 trastuzumab Herceptin R 55 Teysuno 55 GW# [003] 55 cetuximab Erbitux ® 55 Percutaneous Coronary Intervention 55 DP b# 55 vinca alkaloid 55 RECIST criteria 55 ESWL 55 retroperitoneal 55 Gastrointestinal Stromal Tumors 55 urothelial carcinoma 55 Critical Limb Ischemia CLI 55 PSADT 55 SCr 55 symptomatic BPH 55 prospective multicenter study 55 Feasibility Trial 55 TAXUS Liberte Stent 55 P#Y# [002] 55 dexanabinol 55 tipranavir 55 timepoints 55 tumor recurrence 55 azathioprine 55 SUTENT 55 incisional 55 custirsen 55 anti angiogenic therapy 55 restenotic lesions 55 advanced NSCLC 55 transthoracic echocardiography 55 subcutaneous enoxaparin 55 warfarin therapy 55 prospectively stratified 55 treatment naive genotype 55 ER CHOP 55 FOLFOX 55 ipsilateral stroke 55 plasma kallikrein inhibitor 55 DES implantation 55 SYN# 55 HCV RESPOND 2 55 dose escalation Phase 55 piperacillin tazobactam 54 TYKERB 54 Cimzia TM 54 MAGE A3 ASCI 54 TAXOTERE R 54 Vascular Wrap TM 54 VTE prophylaxis 54 autologous transplants 54 bladder carcinoma 54 brain metastases 54 Nexavar sorafenib 54 malignant pleural mesothelioma 54 chronic GVHD 54 BARACLUDE ® 54 Neulasta ® 54 prostate cancer CRPC 54 AKT inhibitor 54 Coronary Artery Bypass Graft 54 PEG interferon 54 GOUT 54 lymphoma CTCL 54 stem cell transplantation 54 biliary strictures 54 certolizumab 54 vincristine doxorubicin 54 INCB# [003] 54 CG# [003] 54 prior relapsers 54 fluvastatin 54 lopinavir r 54 metastatic gastric 54 CANCIDAS 54 Cystectomy 54 Peginterferon 54 tyrosine kinase inhibitor 54 RoACTEMRA 54 adjuvant therapies 54 cyclophosphamide doxorubicin vincristine 54 STRIDE PD 54 NeuroStar TMS Therapy 54 splenectomized patients 54 RIGScan R 54 mCRPC 54 IV tPA 54 plus ribavirin 54 ALT flares 54 laparoscopic partial nephrectomy 54 refractory MCL 54 CML CP 54 LPV r 54 adefovir 54 intermittent dosing 54 pharmacokinetic PK study 54 deferiprone 54 Radical prostatectomy 54 revascularization procedures 54 zotarolimus eluting stent 54 bypass graft CABG surgery 54 BCR ABL inhibitor 54 alemtuzumab Campath 54 5 fluorouracil 54 asymptomatic carotid stenosis 54 alkylating agent 54 cisplatin 54 Operative mortality 54 opioid analgesia 54 azacytidine 54 TEVAR 54 sitaxsentan 54 hypomethylating agents 54 gout flares 54 achieved sustained virologic 54 acute coronary syndromes ACS 54 VESTAsync 54 lymphoid malignancies 54 regorafenib 54 TRX1 54 Solid Tumors criteria 54 Apoptone 54 methylprednisolone 54 everolimus eluting stent 54 secondary efficacy endpoint 54 leukemia CLL 54 oral Hycamtin 54 palliation 54 Phase #b/#a clinical 54 #:# randomization 54 situ CIS 54 cidofovir 54 dose cohorts 54 bevacizumab Avastin R 54 forodesine